Spago Nanomedical and Charles River Laboratories announce agreement forpreclinical studies of SpagoPix
Spago Nanomedical has selected Charles River Laboratories, a leading global CRO, to conduct regulatory preclinical toxicology and safety studies of SpagoPix before clinical trials.The SpagoPix project is advancing towards clinical trials and the product candidate SN132D has shown good effect and safety in pilot tests. The agreement with Charles River covers GLP-studies aiming for generation of regulatory toxicity and safety data that are required for initiation of first-in-man studies. Production of SN132D to cater for the amounts needed in the regulatory preclinical program is ongoing.